WO2023177930A3 - Nasal anti-cancer therapies - Google Patents

Nasal anti-cancer therapies Download PDF

Info

Publication number
WO2023177930A3
WO2023177930A3 PCT/US2023/060160 US2023060160W WO2023177930A3 WO 2023177930 A3 WO2023177930 A3 WO 2023177930A3 US 2023060160 W US2023060160 W US 2023060160W WO 2023177930 A3 WO2023177930 A3 WO 2023177930A3
Authority
WO
WIPO (PCT)
Prior art keywords
msc
derived
cancer therapies
oncolytic virus
nasal anti
Prior art date
Application number
PCT/US2023/060160
Other languages
French (fr)
Other versions
WO2023177930A2 (en
Inventor
Oren MOSKOVICH
Nitzan LEVY
Ariel ANGEL
Original Assignee
Orgenesis, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orgenesis, Inc filed Critical Orgenesis, Inc
Publication of WO2023177930A2 publication Critical patent/WO2023177930A2/en
Publication of WO2023177930A3 publication Critical patent/WO2023177930A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.
PCT/US2023/060160 2022-01-06 2023-01-05 Nasal anti-cancer therapies WO2023177930A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263296953P 2022-01-06 2022-01-06
US63/296,953 2022-01-06
US202263370189P 2022-08-02 2022-08-02
US63/370,189 2022-08-02
US202263385222P 2022-11-29 2022-11-29
US63/385,222 2022-11-29

Publications (2)

Publication Number Publication Date
WO2023177930A2 WO2023177930A2 (en) 2023-09-21
WO2023177930A3 true WO2023177930A3 (en) 2023-12-28

Family

ID=88024318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060160 WO2023177930A2 (en) 2022-01-06 2023-01-05 Nasal anti-cancer therapies

Country Status (1)

Country Link
WO (1) WO2023177930A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200140824A1 (en) * 2018-11-06 2020-05-07 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
US20210260141A1 (en) * 2018-07-18 2021-08-26 Exostem Biotec Ltd. Msc- and exosome-based immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260141A1 (en) * 2018-07-18 2021-08-26 Exostem Biotec Ltd. Msc- and exosome-based immunotherapy
US20200140824A1 (en) * 2018-11-06 2020-05-07 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy

Also Published As

Publication number Publication date
WO2023177930A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
Hernández et al. Differentiation of human mesenchymal stem cells towards neuronal lineage: clinical trials in nervous system disorders
US10226488B2 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2019035880A8 (en) Purified mesenchymal stem cell exosomes and uses thereof
WO2016130591A3 (en) Enhanced delivery of viral particles to the striatum and cortex
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
Jefferson et al. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer
MX2018010828A (en) Colony forming medium and use thereof.
WO2023177930A3 (en) Nasal anti-cancer therapies
IN2014KN02672A (en)
JOP20210186A1 (en) Prostate neoantigens and their uses
Ghasemi-Kasman et al. Enhanced neurogenesis in degenerated hippocampi following pretreatment with miR-302/367 expressing lentiviral vector in mice
MX2022005815A (en) Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70.
WO2017059177A3 (en) Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
WO2021030225A3 (en) Aav capsid variants for targeting human glioblastoma cells
Szablowska-Gadomska et al. Treatment with small molecules is an important milestone towards the induction of pluripotency in neural stem cells derived from human cord blood
Mirakhori et al. Induced neural lineage cells as repair kits: so close, yet so far away
Parameswaran et al. Pluripotent stem cells: A therapeutic source for age-related macular degeneration
CN205149906U (en) A shallow for transporting double gas cylinder
Stukach Stem cells migration to the brain through cranial nerves endings
MY188494A (en) High-growth enterovirus 71 strains and vaccines
CN206394672U (en) Cylinder sleeve of engine travelling bogie
Ren et al. Bone marrow mesenchymal stem cell transplantation enhances angiogenesis and functional recovery after cerebral ischemia in rats
YAN et al. Improved genetic algorithm for robotic cell scheduling problem with flexible processing times
Zhang et al. Expression of lentivirus-mediated rat prodynorphin gene in bone marrow mesenchymal stem cells
MX2023004811A (en) Chimeric antigen receptor (car) nk cells and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771496

Country of ref document: EP

Kind code of ref document: A2